Risk factor
Negligible price volatility
Strong & resilient to price shocks
Good trading liquidity
Profitability factor
Very strong margins and returns
Somewhat favourable analyst view
Greatly overvalued vs peers
Risk / Profitability
Risk: Low
Profitability: Average
Risk factor
Negligible price volatility
Strong & resilient to price shocks
Good trading liquidity
Profitability factor
Very strong margins and returns
Somewhat favourable analyst view
Greatly overvalued vs peers
¥ 7510
About
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and...
About
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the...
